Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;22(5):589-590.
doi: 10.1016/S1473-3099(22)00176-1. Epub 2022 Mar 16.

Antibody durability at 1 year after Sputnik V vaccination

Lautaro Sanchez  1 , Santiago Oviedo Rouco  1 , Marina Pifano  2 , Diego S Ojeda  1 , Carla A Pascuale  1 , Bianca Mazzitelli  3 , Facundo Di Diego Garcia  3 , María M Gonzalez Lopez Ledesma  1 , Pamela E Rodriguez  1 , Esteban A Miglietta  1 , Ana Ceballos  3 , Andrés H Rossi  1 , Nicolas Kreplak  2 , Jorge Geffner  3 , Andrea V Gamarnik  4
Affiliations

Antibody durability at 1 year after Sputnik V vaccination

Lautaro Sanchez et al. Lancet Infect Dis. 2022 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

LS, SOR, MP, and DSO contributed equally. We declare no competing interests.

Figures

Figure
Figure
Longitudinal analysis of humoral response up to 1 year after two doses of Sputnik V vaccine (A) IgG anti-spike antibody concentrations quantified according to the WHO International Standard. Antibodies were measured at 42 (n=100), 180 (n=100), and 360 (n=100) days after completion of the two-dose vacination schedule. (B) Neutralising titres measured at 50% inhibition against the pseudotyped virus (CoV2pp GFP) for the same cohort as in panel A. Each datapoint indicates one volunteer, the horizontal lines at each timepoint show the mean titre, with error bars showing 95% CIs. Wilcoxon matched-pair test was used.
See this image and copyright information in PMC

References

    1. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–681. - PMC - PubMed
    1. Ojeda DS, Gonzalez Lopez Ledesma MM, Pallarés HM, et al. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog. 2021;17 - PMC - PubMed
    1. Schmidt F, Muecksch F, Weisblum Y, et al. Plasma neutralization of the SARS-CoV-2 omicron variant. N Engl J Med. 2022;386:599–601. - PMC - PubMed
    1. Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 omicron variant. Nat Med. 2022 doi: 10.1038/s41591-021-01676-0. published online Jan 19. - DOI - PMC - PubMed
    1. Gonzalez Lopez Ledesma MM, Sanchez L, Ojeda DS, et al. Longitudinal study after Sputnik V vaccination shows durable SARS-CoV-2 neutralizing antibodies and reduced viral variant escape to neutralization over time. mBio. 2022 doi: 10.1128/mbio.03442-21. published online Jan 25. - DOI - PMC - PubMed